ArticleACS omega2022
Human miRNAs to Identify Potential Regions of SARS-CoV-2.
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Polyphyllin VII enhances the sensitivity of endometrial carcinoma cells to medroxyprogesterone acetate through upregulating miR‑33a‑5p expression.Oncology letters · 2025Article
- Profiling of Differentially Expressed MicroRNAs in Human Umbilical Vein Endothelial Cells Exposed to Hyperglycemia via RNA Sequencing.Life (Basel, Switzerland) · 2023Article
- Phytochemistry, Bioactivities of Metabolites, and Traditional Uses ofMolecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is two years now but the world is still struggling against COVID-19 due to the havoc created by the SARS-CoV-2 virus and its multiple variants. Considering this perspective, in this work, we have hypothesized a new approach in order to identify potential regions in SARS-CoV-2 similar to the human miRNAs. Thus, they may have similar consequences as caused by the human miRNAs in human body. Therefore, the same way by which human miRNAs are inhibited can be applied for such potential regions of virus as well by administering drugs to the interacting human proteins. In this regard, the multiple sequence alignment technique Clustal Omega is used to align 2656 human miRNAs with the SARS-CoV-2 reference genome to identify the potential regions within the virus reference genome which have high similarities with the human miRNAs. The potential regions in virus genome are identified based on the highest number of nucleotide match, greater than or equal to 5 at a genomic position, for the aligned miRNAs. As a result, 38 potential SARS-CoV-2 regions are identified consisting of 249 human miRNAs. Among these 38 potential regions, some top regions belong to nucleocapsid, RdRp, helicase, and ORF8. To understand the biological significance of these potential regions, the targets of the human miRNAs are considered for KEGG pathways and protein-protein and drug-protein interaction analysis as the human miRNAs are similar to the potential regions of SARS-CoV-2. Significant pathways are found which lead to comorbidities. Subsequently, drugs like emodin, bicalutamide, vorinostat, etc. are identified that may be used for clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.